96-13: Non-vitamin K Antagonist Oral Anticoagulant and Warfarin as Periprocedural Oral Anticoagulation Therapy of Catheter Ablation for Atrial Fibrillation: J-CARAF Study

  • Murakawa Y
  • Nogami A
  • Shoda M
  • et al.
N/ACitations
Citations of this article
9Readers
Mendeley users who have this article in their library.

Abstract

Purpose and Method: Japanese Heart Rhythm Society requested electrophysiology (EP) centers to register the data of patients who underwent catheter ablation for atrial fibrillation (AF), Japanese Cather Ablation Registry of AF [J-CARAF]. We assessed how the periprocedural use of a NOAC (non-vitamin K antagonist oral anticoagulant) was associated with the incidence of bleeding and stroke events. Result(s): Two hundred and four EP centers reported the data of 4698 AF ablation cases (63.2 + 10.6 year old, male; 74.0%, paroxysmal AF; 64.2%). As a periprocedural OAC, warfarin and NOACs were given in 2568 (54.7%) and in 2130 subjects (dabiagtran 1027 [21.9%], rivaroxaban 606 [12.9%], and apixaban 497 [10.6%]), respectively. Ischemic stroke and bleeding complications such as pericardial effusion occurred in three and 100 patients, respectively (2.2%). No inter-OAC differences in the incidence of complications were detected (2.6 %, 1.5%, 2.3%, 1.2%: above mentioned order). Dabigatran was given in significantly younger subjects with lower CHA2DS2-VASc scores (warfarin vs. dabigatran = 1.95 + 1.48 vs. 1.59 + 1.35, p , 0.05). Multivariate logistic regression analysis did not reveal the influence of any NOAC on adverse events. Only chronic hemodialysis seemed to have increased the number of events (p = 0.003, odds ratio 4.30 [1.62-11.38]). However, when three NOACs were collectively analyzed, they were barely associated with the lower incidence of complications (p , 0.05, OR 0.65 [0.42-0.99]). Conclusion(s): These results suggest that NOACs when used as a periprocedural OAC of AF ablation do not increase the incidence of ischemic stroke or bleeding events.

Cite

CITATION STYLE

APA

Murakawa, Y., Nogami, A., Shoda, M., Inoue, K., Naito, S., Kumagai, K., … Okumura, K. (2016). 96-13: Non-vitamin K Antagonist Oral Anticoagulant and Warfarin as Periprocedural Oral Anticoagulation Therapy of Catheter Ablation for Atrial Fibrillation: J-CARAF Study. EP Europace, 18(suppl_1), i62–i62. https://doi.org/10.1093/europace/18.suppl_1.i62c

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free